A little less than two years after San Francisco’s Mirum Pharmaceuticals ponied up $210 million to acquire Travere Therapeutics’ bile acid portfolio, the deal has paid off with a fresh FDA approval. More: After asset purchase from Travere, Mirum's Ctexli
read moreA new awareness campaign from Abbott highlights a major sticking point in diabetes management: the harmful impact of societal stereotypes and misconceptions about the condition. More: Abbott's stigma-busting campaign shows how diabetes biases lead to silence, skipped care Source: fierce
read moreThe combined company will offer a diverse portfolio of women’s healthcare pills and inserts, including birth control offerings and menopause drugs. More: Cosette sets sights on women's healthcare stardom with 0M Mayne Pharma buy Source: fierce
read moreThe FDA has officially declared an end to the supply squeeze on Novo Nordisk’s GLP-1 drug semaglutide for diabetes and obesity in the U.S. The update will likely put pressure on compounding pharmacies, which have raked in major revenues marketing
read morePrivate equity firms Carlyle and SK Capital have agreed to pay $29 million to acquire bluebird bio, which has struggled to commercialize three gene therapy products. More: Once valued at B, bluebird bio sold to private equity firms for M
read more© 1994 - 2025 B.M. Pharmaceuticals